Below is the information acquired on CELGENE CORP, which is not yet included in our research perimeter.

To request an evaluation of this company and its inclusion in the OpenCorporation Ranking or if you have additional, different and more updated data than what is published in this OpenCorporation company card, please write to info@opencorporation.org so that our team may take it in account.

Last update 31 March 2022

Description of economic activities

Manufacture of pharmaceutical preparations (NACE2 2120)

This company operates as an American integrated biopharmaceutical firm that specialises in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immunological diseases through regulation of genomic and proteomic targets. It was established in 1986. Its corporate headquarters is located in Summit, New Jersey. The company is a global leader in biotechnology. It produces drug therapies for cancer and inflammatory disorders with the goal of delivering quality results for better healthcare. Its products include REVLIMID (lenalidomide), THALOMID (thalidomide), ALKERAN (melphalan), FOCALIN (dexmethylphenidate HCl) cellular and tissue therapeutics, as well as the RITALIN family of drugs. REVLIMID is used for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk MDS (myelodysplastic syndromes) associated with a deletion 5q cytogenetic abnormality. The THALOMID is approved for the treatment of certain conditions associated with Erythema Nodosum Leprosum (ENL) and for newly diagnosed multiple myeloma patients. ALKERAN was in-licensed from GlaxoSmithKline for the treatment of multiple myeloma. RITALIN and FOCALIN are used as a treatment of attention deficit disorder and attention deficit hyperactivity disorder (ADHD) in children and adolescents. The company focuses on putting patients first through helping to provide a broad access of its innovative therapies' clinical benefits. It created a resource healthcare provider called Patient Support Solutions (PSS). The PSS program allows healthcare provider to inquire about and arrange for reimbursement and insurance assistance. The company has a collaborative agreement with Novartis Pharma AG for the development and commercialization of FOCALIN XRTM.
  • CELGENE CORP

  • United States of America (US)
  • Company type: Corporate
  • Parent company: BRISTOL-MYERS SQUIBB COMPANY
  • Chief Executive Officer (CEO): Dr. Giovanni Caforio
  • CEO Total remuneration: N/A
  • Website: www.celgene.com

Financial data

Number of employees

N/A
N/A
N/A
8,852

Revenue 1

N/A
N/A
N/A
13

EBIT 1

N/A
N/A
N/A
5

EBITDA 1

N/A
N/A
N/A
5

1 numbers are in millions

  • RepRisk Indicator (last month):  N/A

Social dialog

  • Transnational Corporate Agreement (TCA): N/A
  • Global Framework Agreement (GFA): N/A
  • Societas Europaea (SE): N/A
  • Bangladesh Accord: N/A

European Works Councils

  • EWC: N/A

Standards and certifications

  • Global Compact: N/A
  • CDP (Carbon Disclosure Project): N/A
  • Modern Slavery Statement: N/A
  • Transparency Index: N/A
  • SA8000 Social Accountability: N/A
  • Integrated report: N/A
  • ISO26000: N/A
  • OECD Guidelines: N/A
  • Social Development Goals (SDGs):

Global Reporting Initiative certification

  • Global Reporting Initiative standards:
  • Global Reporting Initiative GRI G4: N/A

Other company declarations

  • Corporate Social Responsability:
    N/A
  • Accessibility: N/A

Policies

  • Training policy:
  • Policy to protect the right to health and safety in the workplaces where the company operates:
  • Policy to protect the right to health and safety in the workplaces in the supply chain:
  • Diversity policy:

Universal declarations

Declarations and treaties recognised by the country where the company has its registered office

  • Universal Declaration of Human Rights:
  • European Convention on Human Rights (ECHR):
  • Charter of Fundamental Rights of CDFL Workers (Strasbourg Charter 1989):
  • Charter of Fundamental Rights of the European Union EU CFR (Nice Charter 2000):
  • Treaty on the Functioning of the European Union TFEU:
  • Registered office in an OECD country:
  • ILO C029 - Forced Labour Convention, 1930 (No. 29):
  • ILO C087 - Freedom of Association and Protection of the Right to Organise Convention, 1948 (No. 87):
  • ILO C098 - Right to Organise and Collective Bargaining Convention, 1949 (No. 98):
  • ILO C100 - Equal Remuneration Convention, 1951 (No. 100):
  • ILO C105 - Abolition of Forced Labour Convention, 1957 (No. 105):
  • ILO C111 - Discrimination (Employment and Occupation) Convention, 1958 (No. 111):
  • ILO C138 - Minimum Age Convention, 1973 (No. 138):
  • ILO C182 - Worst Forms of Child Labour Convention, 1999 (No. 182):

Directives applied in the company offices in EU 27

  • D. 80/987/EEC: N/A
  • D. 89/391/EEC: N/A
  • D. 98/59/EC: N/A
  • D. 2000/43/EC: N/A
  • D. 2000/78/EC: N/A
  • D. 2001/23/EC: N/A
  • Council D. 2001/86/EC: N/A
  • D. 2002/14/EC: N/A
  • D. 2002/73/EC: N/A
  • Council D. 2003/72/EC: N/A
  • EP and Council D. 2005/56/EC: N/A
  • D. 2009/38/EC: N/A
  • D. 2004/25/EC: N/A
  • D. 2011/35/EU: N/A

Presence in main rankings

  • Global 100 Most Sustainable Corporations: N/A
  • Global CSR Rep Trak 100: N/A
  • BrandZ Top 100 Most Valuable US Brands: N/A
  • The Worlds Best Multinational Workplaces: N/A
  • The Gartner Supply Chain Top 25: N/A
  • The Worlds Most Innovative Companies: N/A
  • The Diversity Inc Top 50 Companies: N/A
  • Best Global Websites: N/A
  • Green Ranking Global Top 500: N/A
  • Green Ranking Global Top 100: N/A

Reference trade unions